Philips Visual Patient Avatar pioneers at-a-glance patient data for faster, better decision-making in the operating room
October 13, 2023
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Visual Patient Avatar, a revolutionary new monitoring solution that translates critical, yet complex patient data into a straightforward visual design as an easy-to-understand avatar display.
In today’s operating rooms (ORs), time constraints and information overload contribute to poor situational awareness, which is responsible for 81.5% of anesthesia-related errors . In the past, monitors in the OR told the patient’s story by displaying vital signs and numbers that took time to interpret, potentially affecting the caregiver’s ability to absorb information and make timely clinical decisions. Visual Patient Avatar is designed to improve situational awareness with ground-breaking elegance by visualizing vital information through animations, colors and shapes. By glancing at a monitor with Visual Patient Avatar, anesthesiologists and nurse anesthetists can recall and process critical data more quickly, efficiently and confidently – ultimately helping to save lives. This new view has the potential to provide clinical teams with the peace of mind to concentrate on what matters most and prepare for what may come next.
A uniquely inspired design to improve situational awareness
Visual Patient Avatar was designed in partnership with two clinicians at the Visualization Technology Research Group at the Institute of Anesthesiology, University Hospital of Zürich. The inspiration for Visual Patient Avatar came from a hobby of the two clinicians, flying airplanes. During flights, an airplane’s dashboard uses synthetic vision technology to share straightforward illustrations that mirror flight environments. This visual representation of what is going on around them has been found to help pilots confidently make flight-related decisions. The clinicians saw the benefit of deploying a similar visual approach to patient monitors, believing that presenting data and information in a simple, visual way that has a logical commonality to the patient could help reduce human error in the OR.
“Created by anesthesiologists for anesthesiologists and nurse anesthetists, the intentionally simple design of Visual Patient Avatar is having a profound impact on clinical confidence and addressing cognitive overload,” said Christoph Pedain, General Manager, Hospital Patient Monitoring at Philips. “By helping clinical care teams make timely decisions without losing their cognitive focus, they can prepare for what may come next – improving patient outcomes and saving lives.”
Proven results in the real-world setting
The launch of Visual Patient Avatar is the latest example of Philips’ long-standing commitment to providing clinicians with reliable clinical decision support. To ensure the design of the Visual Patient Avatar would provide clinicians with the support they need in their daily roles, Philips and University Hospital of Zürich together conducted studies with over 150 clinicians in two Swiss hospitals to validate and refine Visual Patient Avatar using a range of proven methods. Key findings include:
- Compared to the identical conventional monitoring scenarios, Visual Patient Avatar more than doubled the number of vital signs participants could recall after 3- and 10-second looks at the monitor. 
- Visual Patient Avatar increased the percentage of perceived vital signs by 57% when viewed for 10 seconds, and the perceived workload for the task decreased by 12%. 
- During the first use of Visual Patient Avatar, 73% of all vital sign information was correctly identified. 
“Both flying planes and caring for patients involve continuous evaluation of critical parameters in high-stakes environments,” agreed David Tscholl, MD and Christoph Nöthiger, MD, consulting Anesthesiologists at University Hospital of Zürich. “As licensed pilots and anesthesiologists, we know the impact that situational awareness has on the successful outcome of our tasks and the safety of those who are affected by our work. In the air and in the OR. We had a vision to simplify the way critical information is presented in clinical settings and working with Philips to help bring this vision to life is sure to help revolutionize care.”
On Sunday, October 15 from 12-12:30 pm PST at the exhibit hall Center Stage, the co-creators of Visual Patient Avatar, Drs. David Tscholl and Christoph Nöthiger of University Hospital of Zürich, will present data highlighting Visual Patient Avatar's effectiveness at the American Society of Anesthesiologists conference in San Francisco (October 13-17, 2023).
Visual Patient Avatar will be available as an option on select IntelliVue patient monitors in 185 countries. For more information on Philips Visual Patient Avatar, please visit www.philips.com/visual-patient-avatar.
 Schulz et al. BMCA. 2016, Anesthesiology. 2017.
 MC Anesthesiol. 2016;16(14) doi: 10.1186/s12871-016-0172-7 2 Tscholl DW, Handschin L, Neubauer P, et al. Using an animated patient avatar to improve perception of vital sign information by anesthesia professionals. British Journal of Anaesthesia. 2018;121(3):662-671. doi: 10.1016/j.bja.2018.04.024
 Garot O, Rossler J, Pfarr J, et al. Avatar-based versus conventional vital sign display in a central monitor for monitoring multiple patients: a multicenter computer-based laboratory study. BMC Medical Informatics and Decision Making.2020;20(26). doi.org/10.1186/s12911-020-1032-4
 6 Wetli DJ, Bergauer L, Nothiger CB, et al. Improving Visual-Patient-Avatar Design Prior to Its Clinical Release: A Mixed Qualitative and Quantitative Study. Diagnostics (Basel). 2022;12(2):555.5. doi.org/10.3390/diagnostics12020555
For further information, please contact:
Philips Global Press Office
Tel.: +1 724-584-8991
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
- Philips Visual Patient Avatar in the OR
- Infographic: Visual Patient Avatar: A new way to see patient vitals takes shape
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
XPENG G9 Achieves a Five-Star 2023 Safety Rating from Euro NCAP6.12.2023 11:00:00 CET | Press release
The new XPENG G9, now on sale in Europe, received a five-star 2023 safety rating from Euro NCAPThis is XPENG's second five-star safety rating for an international model following the new P7 in October; and its first SUV obtained both Euro NCAP and C-NCAP five-star ratings AMSTERDAM, Dec. 06, 2023 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces that the international model of their flagship electric SUV, XPENG G9, has received a five-star 2023 safety rating from Euro NCAP. Euro NCAP's five-star safety rating system aims to help consumers, their families and businesses compare vehicles more easily and identify the safest choice for their needs. The tests, which replicate real-life road danger scenarios, represent the European gold standard for comprehensive automotive safety testing. The rating recognises the XPENG G9's advanced body structure and comprehensive passive s
AS Tallink Grupp: Managers’ Transactions6.12.2023 11:00:00 CET | Press release
Person subject to the notification requirement Name: AS Infortar Position: Closely associated person (X) Legal person Person Discharging Managerial Responsibilities in Issuer Name: Hanschmidt, Ain Position: Member of the Supervisory Board Name: Pant, Eve Position: Member of the Supervisory Board Issuer: AS Tallink Grupp LEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification _____________________________________ Transaction date: 04.12.2023 Venue: Nasdaq OMX Tallinn Instrument type: Share ISIN: EE3100004466 Nature of the transaction: Acquisition Transaction details: (1): Volume: 105,178; Unit price: 0.68 EUR Aggregated transactions: (2): Volume: 105,178; Volume weighted average price: 0.68 EUR Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn E-mail Anneli.firstname.lastname@example.org
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy6.12.2023 11:00:00 CET | Press release
ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study (NCT06006585) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 as a potential treatment for GA. GA is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD) impacting the ability to see. More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind. GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90. Consequently, risi
ForFarmers N.V.: Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o.6.12.2023 10:30:00 CET | Press release
Lochem, 6 December 2023 Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o. Today, ForFarmers received approval from the Polish competition authority to acquire Piast Pasze Sp. z.o.o. ("Piast"). With this transaction, announced on 25 July 2023, ForFarmers/Tasomix's volume in Poland will expand by 410,000 tonnes, strengthening its position in the broiler sector in particular. Parties will work towards a closing of the acquisition. This transaction is in line with ForFarmers/Tasomix's strategic objectives to expand in the attractive Polish agricultural market. This press release contains information that qualifies as inside information within the meaning of Article 7 paragraph 1 of the EU Market Abuse Regulation. Note to the editor / For further information: Floor van Maaren, T: 06-29597746 Paweł Świerkula, Managing Director ForFarmers/Tasomix M + 48 510 22 00 22 • E: email@example.com About ForFarmers ForFarmers N.V. is an international organisation tha
Resultat af auktion over 1,75 pct. Danske Stat 2025 og 2,25 pct. Danske Stat 20336.12.2023 10:26:31 CET | pressemeddelelse
Bud, salg, skæringspris, pro rata og effektiv rente fremgår af nedenstående oversigt: ISINBud mio. kr. (nominelt)SalgSkæringskursPro-rataEffektiv rente, pct. p.a.99 23138 1,75% 15/11/20251.8601.10098,34100 %2,6499 24532 2,25% 15/11/2033300 300 97,80100 %2,50I alt2.1601.400 Salget bliver afviklet den 8. december 2023.